New Drug Approvals

DECEMBER 3, 2022

Because many cancers have mutations in these genes that allow them to survive, scientists began working to develop drugs that would inhibit this pathway in the 1990s. [1] 1] ABT-737 was superior to previous BCL-2 inhibitors given its higher affinity for Bcl-2, Bcl-xL and Bcl-w. .; Reed, John C.; Shen, Wang; Tahir, Stephen K.;

Small Molecule 52

Small Molecule Clinical Trials Laboratories Regulations 52

The Pharma Data

JUNE 25, 2021

Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Eisai serves as the lead in the co-development of lecanemab.

Disease 40

Disease Treatment Therapies FDA 40

Perficient: Drug Development

MARCH 15, 2024

By December 2009 this investment was worth $1 billion BYD is now in Europe and Southeast Asia, and is already the top EV seller in Australia, Sweden, Thailand, and Israel Not in the US yet for cars, but BYD has become one of the largest electric bus and truck manufacturers, a segment with an easier entry point than passenger vehicles US/China relations (..)

Marketing 52

Marketing Production Government 52

The Pharma Data

JULY 29, 2021

Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Eisai serves as the lead in the co-development of lecanemab and Biogen serves as the lead in the co-development of aducanumab, an anti-A?

Clinical Trials 52

Clinical Trials Treatment Clinical Development Disease 52

DrugBank

JUNE 27, 2023

The general notion is that patients should be viewed individually, rather than strictly as members of some larger general population, and that their specific genetic background, environment, and lifestyle choices should be considered throughout drug development to the point of treatment and continuing patient care.

Disease 98

Disease Treatment Drugs Clinical Trials 98

The Pharma Data

NOVEMBER 29, 2020

Human Cytomegalovirus Resistance to Antiviral Drugs. 2005; 49(3):873-883. . Find out more about HOOKIPA online at www.hookipapharma.com. __. 1 Gilbert C and Boivin G. Antimicrobial Agents and Chemotherapy. Available at: [link] 2 Nephrol Dial Transplant (2013) 28: 2908–2918 3 Centers for Disease Control and Prevention.

Vaccine 40

Vaccine Clinical Trials Disease Therapies 40

Agency IQ

APRIL 19, 2024

MRD in multiple myeloma, specifically: The 2020 guidance states that “significant improvements in clinical outcomes of MM have spurred interest in the use of MRD as a potential surrogate endpoint to expedite drug development.”

FDA 40

FDA Disease Trials Clinical Trials 40

Agency IQ

FEBRUARY 2, 2024

The EMA started providing guidance on the clinical development of anticancer therapeutics in 1996. The document has been updated over time to implement advances in understanding cancer and drug development. In 2005, the guidance was updated to include non-cytotoxic drugs were gaining in importance.

Clinical Trials 40

Clinical Trials Trials Treatment Disease 40

Codon

APRIL 9, 2024

It was only in 2005, after the emergence of widespread resistance of P. falciparum to monotherapy with conventional drugs like chloroquine and sulfadoxine-pyrimethamine, that the WHO recommended treating malaria with drugs in combination with artemisinin. Meanwhile, on the other side of the Pacific, the U.S.

Drugs 139

Drugs Science Research Doctors 139

Alta Sciences

MARCH 4, 2025

Over time, this group of professionals evolved and grew, having regular stakeholder interactions with the FDA and Controlled Substances staff to discuss requirements for drug developers. I have spent the better part of my career working to make drugs safer. About the Author Beatrice Setnik, PhD, Chief Scientific Officer.

Clinical Trials 52

Clinical Trials FDA Drug Development Trials 52

Drug Target Review

NOVEMBER 27, 2024

Introduction Biomarkers are becoming increasingly essential in drug development and clinical practice, driving the need for more precise validation methods. Given this, what’s holding drug developers back? Advanced techniques like MSD and LC-MS/MS offer unmatched precision and sensitivity at a fraction of the cost.

Drug Development 52

Drug Development Regulations Laboratories FDA 52